Showing results (171-180 of 454) with videos related to
Sort By:
Pageof 46
Hepatology (Baltimore, Md.)|May 22, 2012
Droxidopa, an oral norepinephrine precursor, improves hemodynamic and renal alterations of portal hypertensive ratsMar Coll, Sarai Rodriguez, Imma Raurell, et al.Scientific Reports|February 22, 2020
An electronic alert system increases screening for hepatitis B and C and improves management of patients with haematological disordersMar Riveiro-Barciela, Paula Gubern, Luisa Roade, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|October 3, 2009
Hepatitis C viral kinetics during treatment with peg IFN-alpha-2b in HIV/HCV coinfected patients as a function of baseline CD4+ T-cell countsNeumann U Avidan, Deborah Goldstein, Lynn Rozenberg, et al.Hepatology (Baltimore, Md.)|June 17, 2017
The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis BGeorge V Papatheodoridis, Ramazan Idilman, George N Dalekos, et al.Journal of Hepatology|January 26, 2020
Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis BGeorge V Papatheodoridis, Vana Sypsa, George N Dalekos, et al.Journal of Hepatology|February 11, 2018
Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general populationGeorge V Papatheodoridis, Vana Sypsa, George Dalekos, et al.Journal of Neurology|September 11, 2023
Hepatitis B reactivation is a rare event among patients with resolved infection undergoing anti-CD20 antibodies in monotherapy without antiviral prophylaxis: results from the HEBEM studyBlanca Marzo, Angela Vidal-Jordana, Joaquín Castilló, et al.Gastroenterologia Y Hepatologia|May 26, 2023
Chronic liver disease-associated severe thrombocytopenia in Spain: Results from a retrospective study using machine learning and natural language processingJose Luis Calleja-Panero, Rafael Esteban Mur, Isidro Jarque, et al.Transplantation|January 21, 2012
Twelve-week posttreatment follow-up to predict sustained virologic response for recurrent hepatitis C infection in liver recipientsIsabel Campos-Varela, Lluis Castells, Juan Ignacio Esteban, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 18, 2013
Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United StatesJagpreet Chhatwal, Shannon A Ferrante, Cliff Brass, et al.Pageof 46